Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) and Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Profitability
This table compares Conduit Pharmaceuticals and Lipella Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Conduit Pharmaceuticals | N/A | N/A | -328.67% |
| Lipella Pharmaceuticals | -882.82% | -192.33% | -154.24% |
Valuation and Earnings
This table compares Conduit Pharmaceuticals and Lipella Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Conduit Pharmaceuticals | N/A | N/A | -$540,000.00 | N/A | N/A |
| Lipella Pharmaceuticals | $483,533.00 | 7.93 | -$4.62 million | ($4.25) | -0.75 |
Analyst Ratings
This is a breakdown of current recommendations for Conduit Pharmaceuticals and Lipella Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Conduit Pharmaceuticals | 0 | 0 | 0 | 1 | 4.00 |
| Lipella Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Lipella Pharmaceuticals has a consensus price target of $16.00, suggesting a potential upside of 404.73%. Given Lipella Pharmaceuticals’ higher possible upside, analysts plainly believe Lipella Pharmaceuticals is more favorable than Conduit Pharmaceuticals.
Institutional and Insider Ownership
3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 30.9% of Conduit Pharmaceuticals shares are owned by insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Conduit Pharmaceuticals has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
